Navigation Links
CellCyte Genetics Corp. Appoints Tony Colasin as Director of Business Development
Date:11/16/2007

ber 1998 to December 2000. He was a member of Amgen's cross-functional team responsible for the evaluation of drug candidates and management of marketed products for the company's Oncology Franchise. He developed a strong team and led commercial evaluation of oncology-related licensing efforts; he was the finance representative responsible for managing research, a third-party international partnership, and he supported M&A efforts including evaluation of acquisition targets, identifying comparables, determining optimal financing strategy, and supporting SEC filing efforts.

His position as Sr. Finance Manager followed Mr. Colasin's earlier contributions to Amgen as Marketing Manager, from July 1997 to October 1998, and Financial Analyst for the $1 billion+ drug EPOGEN(R), from February 1996 to June 1997. In his early roles with the company, he played a vital part in analyzing forecasts, financial models and sales trends critical to products and markets that the company was pursuing.

Mr. Colasin's initial analyst career was as Sr. Analyst for Putnam, Hayes & Bartlett, Inc., an economic and management consulting firm. With the firm, he diagnosed problems, created analytical frameworks, conducted analyses, developed conclusions, and presented recommendations to senior client management. He also provided analytical support to clients involved in a billion dollar+ licensing agreement dispute, including issues related to reimbursement policies, market penetration and product distribution.

Tony Colasin graduated from University of Southern California with a B.S., Business Administration and received his M.B.A, Finance in International Business Emphasis, in June 2000 from the Anderson School at UCLA.

About CellCyte Genetics

CellCyte Genetics, a Washington State company, is an emerging biotechnology company engaged in the principle business of the discovery, development and commercialization of breakthrough stem cell enabling therapeutic products
'/>"/>

SOURCE CellCyte Genetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Genetics Hold Promise, Challenges for Cancer Care
2. MedImmune Licenses Reverse Genetics Technology to GlaxoSmithKline for Use in Influenza Vaccine Development and Production
3. Salugen to Present Research on Generational Associations of Reward Deficiency Syndrome at XVth World Congress on Psychiatric Genetics
4. Obesity genetics
5. The genetics of MLL leukemogenesis
6. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
7. Clarient Names Michele Hibbard, Ph.D. Director of Genetics
8. Response Genetics Announces Presentation/Webcast at BIOCOM Investor Conference
9. Interleukin Genetics to Host Third Quarter 2007 Financial Results Conference Call November 7
10. Response Genetics to Announce Third Quarter 2007 Financial Results on Wednesday, November 14, 2007
11. Response Genetics Reports Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... When a lifeguard is on duty, it is important for him ... loose clothing. For a lifeguard, comfort can mean not allowing ... the guard prefers to cover up. Comfort also means staying warm ... the clothing that fits correctly. When a lifeguard is spending ... that the guard stays warm and comfortable throughout the shift. ...
(Date:3/3/2015)... NY (PRWEB) March 03, 2015 ... high-quality, clinically-based care management programs and a member ... the appointment of Julie O’Brien as President. O’Brien ... Chief Operating Officer. In her new role, she ... for all aspects of AMM’s call center operations, ...
(Date:3/3/2015)... Dr. Stephen Edgerton, a ... has achieved Accredited Member Status in the American ... this accomplishment after completing a rigorous credentialing process ... the submission of clinical cases for examination. ... up in Connecticut, Charlotte, North Carolina, Caracas, Venezuela ...
(Date:3/3/2015)... (PRWEB) March 03, 2015 ... research networking-technology corporation, announced today that it has ... the Clinical Data Interchange Standards Consortium (CDISC). HCP ... effort to standardize knowledge-based training and certifications globally. ... IT and web support as well as development ...
(Date:3/3/2015)... Aliso Viejo, California (PRWEB) March 03, 2015 ... new animated effect entitled inMotion3D Environment from Pixel Film ... turns a 2D HDRI image into 360° viewing area ... Film Studios. “inMotion3D Environment blurs the line between professional ... , Motion 5 users can turn their 2D HDRI ...
Breaking Medicine News(10 mins):Health News:New Lifeguard Pants Introduced for those Colder Lifeguarding Days 2Health News:New Lifeguard Pants Introduced for those Colder Lifeguarding Days 3Health News:New Lifeguard Pants Introduced for those Colder Lifeguarding Days 4Health News:Julie O'Brien Named President of AliCare Medical Management 2Health News:Julie O'Brien Named President of AliCare Medical Management 3Health News:Dr. Edgerton, a Dentist in Wilmington, NC, Achieves Accredited Status in AACD 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 2Health News:HealthCarePoint Completes CDISC BlueCloud Transnational Commerce Through In-kind Donations 3Health News:A New Plugin Entitled inMotion3D Environment Was Released Today from Pixel Film Studios Exclusively for Motion 5 2
... Delhi is planning to interlink its major 29 hospitals ... and treatment provided. This computerization and interlinking of data ... by which doctors can know the case history and ... modules of software to deal with different hospital departments. ...
... number of psychiatric disorders, including mood disorders, schizophrenia// ... shown to increase the risk for emergence of ... disorder), and that presence of certain anxiety disorders ... development of nicotine dependence. ,A recent study ...
... or growing fast: systematic review of size and growth ... who grow rapidly during the first two years of life, ... a study reveals. ,There is an urgent need to ... is not clear how early in life prevention could begin. ...
... is no link whatsoever between breast cancer and cholesterol levels ... control the same. ,The details of the study ... Internal Medicine, one of the JAMA/Archives journals. The article says ... to suggest that the statins may work in conjunction with ...
... compulsory licensing (CL) provision in the Patents Act that ... Swiss drug maker Roche’s patented drug Tamiflu, useful in ... flu virus. , ,Section 92 empowers the government ... the industry. Furthermore, the issue of such license is ...
... a large, heterogeneous group of rare pulmonary disorders ... abnormal gas exchange with considerable mortality and morbidity. ... diagnosis includes more than 100 conditions in both ... and Colorado conducted a descriptive, observational study was ...
Cached Medicine News:Health News:Delhi Government To Interlink All Major Hospitals Through e-Governance 2Health News:Smokers Are Prone To Number Of Psychiatric Disorders 2Health News:A New Diagnostic Approach To Pediatric Interstitial Lung Disease 2
(Date:3/2/2015)... March 2, 2015 Cure SMA recently announced a ... Biomedical Research (CALIBR). This funding is an extension of a ... a $700,000 Cure SMA grant to Dr. Peter G. ... "Optimization of Small Molecules that Increase SMN2 Levels ... motor neuron (SMN) protein is critical to the function of ...
(Date:3/2/2015)... -- Landauer, Inc. (NYSE: LDR ), a recognized ... outsourced medical physics services and high quality medical consumable ... the fiscal first quarter 2015 after the market close ... Company will also host a conference call for investors ... Time (10:00 a.m. Eastern Time). Investors may access the ...
(Date:3/2/2015)... March 2, 2015 Amgen (NASDAQ: ... abstracts, including data evaluating Repatha TM (evolocumab), an ... investigational drug for chronic heart failure, at the upcoming ... Session (ACC.15), being held March 14-16 in ... fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin ...
Breaking Medicine Technology:Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 2Cure SMA Announces $315,000 Grant to California Institute of Biomedical Research 3Landauer, Inc. Announces Date and Time for Announcement of Fiscal First Quarter 2015 Results and Conference Call 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 2Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 3Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 4Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 5Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 6Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 7Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 8Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 9Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 10Amgen Showcases Cardiovascular Pipeline At ACC.15 With New Cholesterol-Lowering And Chronic Heart Failure Data 11
... Most Up-to-Date Analysis of the Alzheimer,s Disease Market Now ... ... WALTHAM, Mass., July 15 Decision Resources, one ... and,healthcare issues, finds that with Myriad Genetics/Lundbeck,s decision to,discontinue ...
... for diseases of ... ... Pharmaceuticals, Inc.,a privately held biotechnology company located in San Jose, CA, ... from Penwest Pharmaceuticals, Edison,s development,partner. Penwest has begun dosing in a ...
Cached Medicine Technology:Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation 2Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development 2
... U.S. approval in 1992, ABIOMED's BVS 5000 has ... cardiac assist system in the world to support ... by the U.S. Food and Drug Administration for ... ABIOMED continues to make advances with the BVS ...
... Left Ventricular Assist System (LVAS), manufactured by ... used as a destination therapy for patients ... heart failure, for which heart transplantation is ... is not intended as a bridge to ...
... System includes three major components: Blood pump, ... Portable Driver. This system provides partial or ... with conventional therapy, is unable to maintain ... accomplish support, blood flows from the natural ...
Datascope presents a unique new product for post-hemostasis puncture site management. Safeguard is the first product ever to combine a built-in inflatable bulb and a sterile dressing- providing adjus...
Medicine Products: